NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

June 7, 2024

Study Completion Date

June 7, 2024

Conditions

Ovarian CancerOvarian NeoplasmsOvarian CarcinomaEndometrial CancerOvary CancerOvary NeoplasmOvary DiseaseOvary MetastasisOvarian DiseasesOvarian Cancer StageOvarian Epithelial CancerOvarian AdenocarcinomaOvarian Serous AdenocarcinomaOvarian Neoplasm EpithelialOvarian Cancer RecurrentEndometrial DiseasesEndometrial AdenocarcinomaEndometrial CarcinosarcomaEndometrial Clear Cell AdenocarcinomaEndometrioid AdenocarcinomaEndometrial NeoplasmsEndometrial Cancer RecurrentEndometrioid TumorFallopian Tube CancerPeritoneal Cancer

Interventions

DRUG

ELU001

Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Trial Locations (18)

10065

Memorial Sloan Kettering Cancer Center, New York

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

27719

Duke University Medical Center - Duke Cancer Institute, Durham

32224

Mayo Clinic - Jacksonville, FL, Jacksonville

32827

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

33063

D&H Cancer Research Center, Margate

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic - Rochester, MN, Rochester

57105

Avera Cancer Institute, Sioux Falls

60521

Hope and Healing Cancer Services, Hinsdale

61606

OSF Saint Francis Medical Center, Peoria

75230

Mary Crowley Cancer Research, Dallas

78229

New Experimental Therapeutics of San Antonio (NEXT Oncology), San Antonio

85054

Mayo Clinic - Phoenix, AZ, Phoenix

92835

Providence Medical Foundation, Fullerton

98109

Fred Hutchinson Cancer Center, Seattle

02905

Women & Infants Hospital of Rhode Island, Providence